Emerging respiratory viruses: challenges and vaccine strategies.

Clin Microbiol Rev

Laboratory of Infectious Diseases, National Insitute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.

Published: October 2006


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The current threat of avian influenza to the human population, the potential for the reemergence of severe acute respiratory syndrome (SARS)-associated coronavirus, and the identification of multiple novel respiratory viruses underline the necessity for the development of therapeutic and preventive strategies to combat viral infection. Vaccine development is a key component in the prevention of widespread viral infection and in the reduction of morbidity and mortality associated with many viral infections. In this review we describe the different approaches currently being evaluated in the development of vaccines against SARS-associated coronavirus and avian influenza viruses and also highlight the many obstacles encountered in the development of these vaccines. Lessons learned from current vaccine studies, coupled with our increasing knowledge of the host and viral factors involved in viral pathogenesis, will help to increase the speed with which efficacious vaccines targeting newly emerging viral pathogens can be developed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592697PMC
http://dx.doi.org/10.1128/CMR.00005-06DOI Listing

Publication Analysis

Top Keywords

respiratory viruses
8
avian influenza
8
sars-associated coronavirus
8
viral infection
8
development vaccines
8
viral
6
emerging respiratory
4
viruses challenges
4
challenges vaccine
4
vaccine strategies
4

Similar Publications

Background: Respiratory syncytial virus (RSV) is recognized as the primary cause of hospitalizations among children with lower respiratory tract infections in developed countries, placing a significant burden on both patients and healthcare systems. The efficacy, safety, and immunogenicity of maternal vaccination with the novel RSVpreF vaccine have been evaluated in a Phase III clinical trial, showing a decreased risk of severe infection in infants. Our study assesses the cost-effectiveness of the RSVpreF vaccine and seasonal variation of costs in a Norwegian setting.

View Article and Find Full Text PDF

Widely Distributed Pigeon Paramyxovirus Sub-Genotypes Pose a Risk to Immunocompromised Humans.

Zoonoses Public Health

September 2025

Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.

Introduction: Pigeon paramyxovirus type 1 (PPMV-1) is an antigenic variant of Avian Orthoavulavirus 1 (AOAV-1) (Newcastle disease virus) with a global distribution that causes lethal infections in pigeon and dove species. AOAV-1's infecting humans normally cause mild, self-limiting conjunctivitis, but since 2003, PPMV-1 has been associated with an increased number of severe and lethal respiratory and neurological infections in immunocompromised persons in the Netherlands, the USA, France, China and Australia.

Methods: PPMV-1's isolated from free-living pigeons and doves across South Africa from 2012 to 2024 were sequenced using conventional or next generation technologies.

View Article and Find Full Text PDF

Objective: To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).

Methods: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included.

View Article and Find Full Text PDF

Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and young children. The COVID-19 pandemic significantly disrupted global RSV epidemiology. This study aimed to investigate the impact of the pandemic on RSV epidemiology in northern Taiwan from 2018 to 2023.

View Article and Find Full Text PDF

The status of co-infection with porcine reproductive and respiratory syndrome virus type 1 (PRRSV-1) and type 2 (PRRSV-2) in Japan is poorly understood. A case of such co-infection was identified on a PRRSV-1 non-vaccinated farm in Kagoshima prefecture. Both PRRSV-1 and PRRSV-2 genomes were simultaneously detected in pig samples by RT-PCR, and molecular analysis confirmed PRRSV-1/PRRSV-2 co-infection in individual piglets.

View Article and Find Full Text PDF